Developer docs
API playgroundTry for free, no card

Search company profiles

Avance Clinical

Full company profile

uuid0007csl

Namestring
Avance Clinical
Legal namestring
Avance Clinical Pty Ltd.
Websiteurl
avancecro.com
Company typeenum
Private
Founded yearint
1990
Descriptiontext

Avance Clinical is an Australia-headquartered, full-service Contract Research Organization (CRO) that provides clinical trial management services to international biotechnology sponsors across all development phases. Its core offering combines preclinical and regulatory consultancy (ClinicReady), early-phase services leveraging Australia's Clinical Trial Notification scheme (no IND requirement, 5-6 week study start-up timelines), late-phase multi-regional trials, and the proprietary GlobalReady end-to-end drug development model that retains the same CRO team and data quality from Phase I in Australia through late-phase expansion into North America, Asia-Pacific, and Europe. The company supplements this platform with four specialized Centers of Excellence in Oncology, CNS, Renal & Cardiometabolic, and Early Phase, each providing indication-level scientific leadership and dedicated trial design capabilities.

The company operates a 2,000+ site GlobalReady Site Partnership Network across North America and maintains offices in Australia, New Zealand, the United States, the United Kingdom, South Korea, Taiwan, Singapore, Malaysia, mainland China (Shanghai, Beijing), and India. Its technology stack integrates Medidata-trained platform specialists, electronic health records integration, digital patient engagement, and what the company describes as AI-enabled clinical trial management systems. Since 2022, Avance Clinical has been privately held and backed by Riverside following a significant investment that valued the company above $200 million.

The business model is project-based full-service CRO revenue: multi-year contracts with biotech sponsors priced per study scope, phase, and therapeutic area, with no public pricing. Australia's 43.5% R&D tax rebate on eligible clinical spend effectively reduces net cost for sponsors, a key component of the value proposition. Go-to-market is primarily enterprise field sales supplemented by inside sales (website "Request a Proposal" and "Book a Meeting" funnels), with concentrated event presence at BIO International, ASCO, AACR, and BIO-Europe driving top-of-funnel lead generation. The company employs 330+ experienced staff and reports 500+ studies completed, 18,000+ participants recruited, and 70% repeat customer rates over the past five years.

Short descriptiontext

Avance Clinical is an Australia-headquartered global CRO providing full-service clinical trial management for international biotech sponsors across preclinical, early-phase, and late-phase development, leveraging Australia's regulatory advantages and a proprietary GlobalReady model spanning Australia, North America, Asia-Pacific, and Europe.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersAdelaide, Australia
HQ citystring
Adelaide
HQ countrystring
Australia
HQ regionstring
Oceania
Markets served

Serves global market

Offices9 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical research services, contract research organization, early phase trials, biotech clinical development, oncology clinical trials
Industry5 codes
PRIMARYHLAGAAAA
Clinical CROs (Phase I–IV)
SECONDARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)
SECONDARYHLAGAAAB
Preclinical CROs (Discovery/Pharmacology/DMPK)
SECONDARYHLAGAAAG
Medical Writing & Regulatory Submission Support CROs
SECONDARYHLAGAAAH
Pharmacovigilance, Risk Management & Medical Affairs CROs
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Research and Development in the Physical, Engineering, and Life Sciences54171
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Contract Research Organization (CRO) Services
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model1 record
1Contract Research Organization Services
TypeProfessional Services
Description

Avance Clinical generates revenue through full-service contract research organization services for biotech companies, providing clinical trial management from preclinical through Phase I, Phase II, and late-phase studies. Revenue is project-based, typically structured as fixed contracts for defined scope of work.

avancecro.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Pricing details1 tier
1Full-service CRO engagement - pricing varies by study scope, phase, and therapeutic area
ModelOtherBilling cadenceMulti-year contract
Notes

No public pricing available; engagements are custom-quoted based on study requirements, duration, complexity, and geographic scope.

avancecro.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 6 records shown
1GlobalReady
Description

A proprietary process encapsulating the entire drug development journey from robust Early Phase clinical foundations to seamless multi-regional Late phase expansions, retaining the same high quality CRO to reduce time and cost and deliver highest quality data for regulatory approvals.

avancecro.com
+5 more records
Core offering1 text field

Avance Clinical is a full-service Contract Research Organization (CRO) providing clinical trial management services for biotech companies from preclinical through late-phase development. Its offerings span the ClinicReady preclinical consultancy, Phase I and Early Phase trials, Phase II+ and Late Phase multi-regional studies, and the proprietary GlobalReady end-to-end drug development process. The company also operates specialized Centers of Excellence in CNS, Oncology, Renal & Cardiometabolic, and Early Phase, serving biotech sponsors across Australia, North America, Asia, New Zealand, and Europe.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 5-6 weeks to Site Initiation Visit and Study Start in Australia
+4 more records
Product overview1 text field

Avance Clinical is a full-service Contract Research Organization (CRO) offering an integrated platform of clinical trial services for biotech companies. The core offering includes ClinicReady (preclinical and regulatory affairs consultancy), Phase I/Early Phase services, Phase II+/Late Phase services, and the GlobalReady proprietary drug development model spanning all phases across multiple regions. Specialized Centers of Excellence in CNS, Oncology, Renal & Cardiometabolic, and Early Phase provide indication-specific expertise. The company operates across Australia, North America, Asia, New Zealand, and Europe, leveraging Australia's regulatory advantages including rapid ethics approval, no IND requirement, and up to 43.5% R&D tax rebate.

Product and service8 records
1ClinicReady
CategoryPreclinical CRO Services
Description

Preclinical and regulatory affairs consultancy service that helps biotech sponsors demonstrate safety and preliminary clinical Proof of Concept, laying clinical foundations for seamless transition into Phase I. Target users: biotech sponsors preparing for first-in-human studies.

2Phase I / Early Phase Services
CategoryClinical Trial Services — Phase I
Description

Comprehensive Phase I clinical trial services offering fast, agile, and adaptive clinical research solutions for biotechs in early phases of drug development. Target users: biotech sponsors conducting first-in-human and early-phase studies.

3Phase II+ / Late Phase Services
CategoryClinical Trial Services — Late Phase
Description

Multi-regional clinical trial services for Phase II and later, across oncology, CNS, rare diseases, and infectious diseases, leveraging AI and gold standard data and trial management systems. Target users: biotech sponsors running late-stage multi-regional trials.

4GlobalReady
CategoryIntegrated CRO Program
Description

Proprietary end-to-end drug development service retaining the same CRO team from Phase I in Australia through multi-regional late-phase expansion in the US, Asia-Pacific, and Europe, delivering globally accepted data for regulatory approvals. Target users: biotech sponsors seeking a single CRO partner across all development phases and geographies.

5CNS Center of Excellence
CategoryTherapeutic Area CRO Center
Description

Specialized clinical trial services for central nervous system disorders, addressing trial challenges for biotech sponsors developing neurological therapies, supported by experienced leadership and strategic partnerships. Target users: biotech sponsors developing CNS therapeutics.

6Oncology Center of Excellence
CategoryTherapeutic Area CRO Center
Description

Specialized oncology clinical trial services combining indication-level scientific leadership, advanced early-phase trial design, and oncology-focused site networks to support confident progression from first-in-human through Phase II. Target users: biotech sponsors developing oncology therapeutics.

7Renal & Cardiometabolic Center of Excellence
CategoryTherapeutic Area CRO Center
Description

Specialized clinical trial services focused on improving patient recruitment, retention, and speeding up clinical development in renal and cardiometabolic therapeutic areas. Target users: biotech sponsors developing renal and cardiometabolic therapies.

8Early Phase Center of Excellence
CategoryTherapeutic Area CRO Center
Description

Dedicated center accelerating high-quality early-phase trials for emerging biotech sponsors, operating through a globally integrated model across Australia, New Zealand, the United States, the United Kingdom, South Korea, Taiwan, and India. Target users: emerging biotech sponsors requiring rapid early-phase execution.

Scale indicator14 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-24
Description

Partnership for CLD-401 oncolytic virus clinical trials in Australia, facilitating regulatory approval and initiating clinical trials for solid tumor indications. Calidi plans to file IND with FDA in 2026.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-07
Description

Acquisition of U.S.-based specialized oncology CRO with deep expertise in oncology trials, strengthening Avance Clinical's global oncology offering.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-02-26
Description

Strategic partnership agreement signed February 26, 2025, forming collaborative framework between two full-service CROs to deliver globally integrated clinical trial solutions. Partnership enables Simbec-Orion expansion into Australia and Asia-Pacific while extending Avance Clinical capabilities in Europe and UK, combining expertise across 34 countries.

4Mid-Ship Biomedical
Strategic tierSupportingTypeStrategic or Co-development Partner
Description

MOU signed to strengthen global clinical research collaboration between the two organizations.

avancecro.com
5Four Premier Taiwanese Trial Sites
Strategic tierSupportingTypeStrategic or Co-development Partner
Description

MOUs signed with key clinical trial sites in Taiwan providing sponsors priority access to eligible patients and accelerating clinical trial agreement finalization.

avancecro.com
Strategic tierSupportingTypeTechnology or Integration
Description

GMP manufacturer partnership for CLD-401 manufacturing supporting Calidi Biotherapeutics clinical program.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global CRO acquired by Thermo Fisher Scientific offering full-service clinical development across all phases. PPD is a broad incumbent competitor to Avance Clinical in late-phase and multi-regional biotech clinical trials.

TypeBroad incumbent
Description

Large global CRO offering comprehensive clinical development and biopharmaceutical services. Parexel directly competes for multi-regional biotech clinical trial mandates that Avance Clinical also targets under its GlobalReady model.

TypeBroad incumbent
Description

Mid-to-large CRO specializing in clinical development for small and mid-sized biopharma. Medpace competes with Avance Clinical in the biotech-focused CRO segment but with a US-centric operating model and broader scale.

TypeBroad incumbent
Description

One of the world's largest CROs providing full-service clinical development across all phases and therapeutic areas. ICON competes with Avance Clinical for biotech sponsor business but operates at significantly greater scale with broader service offerings.

TypeBroad incumbent
Description

Global CRO formed from the Covance acquisition, providing full-service clinical development and central laboratory services. Labcorp competes with Avance Clinical in early and late-phase trials but with significantly broader infrastructure and central lab capabilities.

TypeDirect peer
Description

Mid-sized global CRO with deep CNS, oncology, and rare disease expertise. Worldwide is a comparable mid-tier competitor targeting similar biotech sponsor profiles with overlapping therapeutic area specializations.

TypeBroad incumbent
Description

The largest global CRO with end-to-end clinical, technology, and data capabilities. IQVIA is a broad incumbent competitor that offers similar multi-regional biotech CRO services as part of a much larger portfolio including RWD and commercial services.

TypeBroad incumbent
Description

Large CRO and preclinical services provider offering research models, discovery, and clinical development support. Charles River competes with Avance Clinical's ClinicReady preclinical offering and selected clinical services, though from a much larger discovery-focused platform.

TypeDirect peer
Description

Mid-sized full-service clinical CRO with strong early-phase and specialty therapeutic expertise. Simbec-Orion is both a strategic partner (Feb 2025 alliance) and a direct peer in the biotech-focused CRO segment, with overlapping therapeutic and geographic coverage.

TypeDirect peer
Description

Asia-Pacific-headquartered full-service CRO focused on biotech clinical trials across the region, with strong early-phase capabilities. Novotech is the most direct geographic and segment competitor to Avance Clinical in the biotech-focused, multi-regional CRO market.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Avance Clinical

Contract Research Organization (CRO) Servicesavancecro.com

Avance Clinical is an Australia-headquartered global CRO providing full-service clinical trial management for international biotech sponsors across preclinical, early-phase, and late-phase development, leveraging Australia's regulatory advantages and a proprietary GlobalReady model spanning Australia, North America, Asia-Pacific, and Europe.

What Avance Clinical does

Avance Clinical is an Australia-headquartered, full-service Contract Research Organization (CRO) that provides clinical trial management services to international biotechnology sponsors across all development phases. Its core offering combines preclinical and regulatory consultancy (ClinicReady), early-phase services leveraging Australia's Clinical Trial Notification scheme (no IND requirement, 5-6 week study start-up timelines), late-phase multi-regional trials, and the proprietary GlobalReady end-to-end drug development model that retains the same CRO team and data quality from Phase I in Australia through late-phase expansion into North America, Asia-Pacific, and Europe. The company supplements this platform with four specialized Centers of Excellence in Oncology, CNS, Renal & Cardiometabolic, and Early Phase, each providing indication-level scientific leadership and dedicated trial design capabilities.

The company operates a 2,000+ site GlobalReady Site Partnership Network across North America and maintains offices in Australia, New Zealand, the United States, the United Kingdom, South Korea, Taiwan, Singapore, Malaysia, mainland China (Shanghai, Beijing), and India. Its technology stack integrates Medidata-trained platform specialists, electronic health records integration, digital patient engagement, and what the company describes as AI-enabled clinical trial management systems. Since 2022, Avance Clinical has been privately held and backed by Riverside following a significant investment that valued the company above $200 million.

The business model is project-based full-service CRO revenue: multi-year contracts with biotech sponsors priced per study scope, phase, and therapeutic area, with no public pricing. Australia's 43.5% R&D tax rebate on eligible clinical spend effectively reduces net cost for sponsors, a key component of the value proposition. Go-to-market is primarily enterprise field sales supplemented by inside sales (website "Request a Proposal" and "Book a Meeting" funnels), with concentrated event presence at BIO International, ASCO, AACR, and BIO-Europe driving top-of-funnel lead generation. The company employs 330+ experienced staff and reports 500+ studies completed, 18,000+ participants recruited, and 70% repeat customer rates over the past five years.

Avance Clinical firmographics

Firmographics
Name
Avance Clinical
Legal name
Avance Clinical Pty Ltd.
Website
https://avancecro.com
Company type
Private
Founded year
1990
Operating status
Operating
Headcount range
251–500 employees
Short description
Avance Clinical is an Australia-headquartered global CRO providing full-service clinical trial management for international biotech sponsors across preclinical, early-phase, and late-phase development, leveraging Australia's regulatory advantages and a proprietary GlobalReady model spanning Australia, North America, Asia-Pacific, and Europe.
Ownership category
akta.pro rank

Avance Clinical industry classification

Industry
Product category
Contract Research Organization (CRO) Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAAAA
Clinical CROs (Phase I–IV)
SECONDARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)
SECONDARYHLAGAAAB
Preclinical CROs (Discovery/Pharmacology/DMPK)
SECONDARYHLAGAAAG
Medical Writing & Regulatory Submission Support CROs
SECONDARYHLAGAAAH
Pharmacovigilance, Risk Management & Medical Affairs CROs

Keywords

  • Clinical research services
  • Contract research organization
  • Early phase trials
  • Biotech clinical development
  • Oncology clinical trials

Where Avance Clinical is headquartered

Location

Headquarters

HQ city
Adelaide
HQ country
Australia
HQ region
Oceania

Offices9 records

Markets served

Avance Clinical business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Contract Research Organization Services: Avance Clinical generates revenue through full-service contract research organization services for biotech companies, providing clinical trial management from preclinical through Phase I, Phase II, and late-phase studies. Revenue is project-based, typically structured as fixed contracts for defined scope of work.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractFull-service CRO engagement - pricing varies by study scope, phase, and therapeutic area

Go-to-market motion3 records

Distribution channels2 records

Marketing channels6 records

Avance Clinical product offering

Product offering

Core offering

Avance Clinical is a full-service Contract Research Organization (CRO) providing clinical trial management services for biotech companies from preclinical through late-phase development. Its offerings span the ClinicReady preclinical consultancy, Phase I and Early Phase trials, Phase II+ and Late Phase multi-regional studies, and the proprietary GlobalReady end-to-end drug development process. The company also operates specialized Centers of Excellence in CNS, Oncology, Renal & Cardiometabolic, and Early Phase, serving biotech sponsors across Australia, North America, Asia, New Zealand, and Europe.

Product overview

Avance Clinical is a full-service Contract Research Organization (CRO) offering an integrated platform of clinical trial services for biotech companies. The core offering includes ClinicReady (preclinical and regulatory affairs consultancy), Phase I/Early Phase services, Phase II+/Late Phase services, and the GlobalReady proprietary drug development model spanning all phases across multiple regions. Specialized Centers of Excellence in CNS, Oncology, Renal & Cardiometabolic, and Early Phase provide indication-specific expertise. The company operates across Australia, North America, Asia, New Zealand, and Europe, leveraging Australia's regulatory advantages including rapid ethics approval, no IND requirement, and up to 43.5% R&D tax rebate.

Differentiator

Problem solved

Functional benefit

Brands

  • GlobalReady: A proprietary process encapsulating the entire drug development journey from robust Early Phase clinical foundations to seamless multi-regional Late phase expansions, retaining the same high quality CRO to reduce time and cost and deliver highest quality data for regulatory approvals.
  • ClinicReady
  • Early Phase Center of Excellence
  • Oncology Center of Excellence
  • CNS Center of Excellence
  • Renal & Cardiometabolic Center of Excellence

Products and services

  • ClinicReady Preclinical and regulatory affairs consultancy service that helps biotech sponsors demonstrate safety and preliminary clinical Proof of Concept, laying clinical foundations for seamless transition into Phase I. Target users: biotech sponsors preparing for first-in-human studies.
  • Phase I / Early Phase Services Comprehensive Phase I clinical trial services offering fast, agile, and adaptive clinical research solutions for biotechs in early phases of drug development. Target users: biotech sponsors conducting first-in-human and early-phase studies.
  • Phase II+ / Late Phase Services Multi-regional clinical trial services for Phase II and later, across oncology, CNS, rare diseases, and infectious diseases, leveraging AI and gold standard data and trial management systems. Target users: biotech sponsors running late-stage multi-regional trials.
  • GlobalReady Proprietary end-to-end drug development service retaining the same CRO team from Phase I in Australia through multi-regional late-phase expansion in the US, Asia-Pacific, and Europe, delivering globally accepted data for regulatory approvals. Target users: biotech sponsors seeking a single CRO partner across all development phases and geographies.
  • CNS Center of Excellence Specialized clinical trial services for central nervous system disorders, addressing trial challenges for biotech sponsors developing neurological therapies, supported by experienced leadership and strategic partnerships. Target users: biotech sponsors developing CNS therapeutics.
  • Oncology Center of Excellence Specialized oncology clinical trial services combining indication-level scientific leadership, advanced early-phase trial design, and oncology-focused site networks to support confident progression from first-in-human through Phase II. Target users: biotech sponsors developing oncology therapeutics.
  • Renal & Cardiometabolic Center of Excellence Specialized clinical trial services focused on improving patient recruitment, retention, and speeding up clinical development in renal and cardiometabolic therapeutic areas. Target users: biotech sponsors developing renal and cardiometabolic therapies.
  • Early Phase Center of Excellence Dedicated center accelerating high-quality early-phase trials for emerging biotech sponsors, operating through a globally integrated model across Australia, New Zealand, the United States, the United Kingdom, South Korea, Taiwan, and India. Target users: emerging biotech sponsors requiring rapid early-phase execution.

Quantifiable outcome

  • 5-6 weeks to Site Initiation Visit and Study Start in Australia
  • +4 more outcomes

Companies that use Avance Clinical

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Avance Clinical technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

Feature4 records

Avance Clinical partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core, major and supporting.

  • Calidi BiotherapeuticscoreStrategic or Co-development Partner · 24 March 2026Partnership for CLD-401 oncolytic virus clinical trials in Australia, facilitating regulatory approval and initiating clinical trials for solid tumor indications. Calidi plans to file IND with FDA in 2026.
  • LumaBridgecoreStrategic or Co-development Partner · 7 January 2026Acquisition of U.S.-based specialized oncology CRO with deep expertise in oncology trials, strengthening Avance Clinical's global oncology offering.
  • Simbec-OrionmajorStrategic or Co-development Partner · 26 February 2025Strategic partnership agreement signed February 26, 2025, forming collaborative framework between two full-service CROs to deliver globally integrated clinical trial solutions. Partnership enables Simbec-Orion expansion into Australia and Asia-Pacific while extending Avance Clinical capabilities in Europe and UK, combining expertise across 34 countries.
  • Mid-Ship BiomedicalsupportingStrategic or Co-development PartnerMOU signed to strengthen global clinical research collaboration between the two organizations.
  • Four Premier Taiwanese Trial SitessupportingStrategic or Co-development PartnerMOUs signed with key clinical trial sites in Taiwan providing sponsors priority access to eligible patients and accelerating clinical trial agreement finalization.
  • Matica BiosupportingTechnology or IntegrationGMP manufacturer partnership for CLD-401 manufacturing supporting Calidi Biotherapeutics clinical program.

Scale indicators14 records

Recent moves7 records

Expansion highlights6 records

Avance Clinical competitors and assessment

Company assessment

Broad incumbents

  • PPD (Thermo Fisher Scientific): Global CRO acquired by Thermo Fisher Scientific offering full-service clinical development across all phases. PPD is a broad incumbent competitor to Avance Clinical in late-phase and multi-regional biotech clinical trials.
  • Parexel: Large global CRO offering comprehensive clinical development and biopharmaceutical services. Parexel directly competes for multi-regional biotech clinical trial mandates that Avance Clinical also targets under its GlobalReady model.
  • Medpace: Mid-to-large CRO specializing in clinical development for small and mid-sized biopharma. Medpace competes with Avance Clinical in the biotech-focused CRO segment but with a US-centric operating model and broader scale.
  • ICON plc: One of the world's largest CROs providing full-service clinical development across all phases and therapeutic areas. ICON competes with Avance Clinical for biotech sponsor business but operates at significantly greater scale with broader service offerings.
  • Labcorp Drug Development: Global CRO formed from the Covance acquisition, providing full-service clinical development and central laboratory services. Labcorp competes with Avance Clinical in early and late-phase trials but with significantly broader infrastructure and central lab capabilities.
  • IQVIA: The largest global CRO with end-to-end clinical, technology, and data capabilities. IQVIA is a broad incumbent competitor that offers similar multi-regional biotech CRO services as part of a much larger portfolio including RWD and commercial services.
  • Charles River Laboratories: Large CRO and preclinical services provider offering research models, discovery, and clinical development support. Charles River competes with Avance Clinical's ClinicReady preclinical offering and selected clinical services, though from a much larger discovery-focused platform.

Direct peers

  • Worldwide Clinical Trials: Mid-sized global CRO with deep CNS, oncology, and rare disease expertise. Worldwide is a comparable mid-tier competitor targeting similar biotech sponsor profiles with overlapping therapeutic area specializations.
  • Simbec-Orion: Mid-sized full-service clinical CRO with strong early-phase and specialty therapeutic expertise. Simbec-Orion is both a strategic partner (Feb 2025 alliance) and a direct peer in the biotech-focused CRO segment, with overlapping therapeutic and geographic coverage.
  • Novotech: Asia-Pacific-headquartered full-service CRO focused on biotech clinical trials across the region, with strong early-phase capabilities. Novotech is the most direct geographic and segment competitor to Avance Clinical in the biotech-focused, multi-regional CRO market.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Avance Clinical social profiles

Digital presence

Avance Clinical financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Avance Clinical leadership team

Management profile

Number of profiles

Profiles11 records

Avance Clinical subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Avance Clinical funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Avance Clinical M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Avance Clinical

What does Avance Clinical do?

Avance Clinical is a full-service Contract Research Organization (CRO) providing clinical trial management services for biotech companies from preclinical through late-phase development. Its offerings span the ClinicReady preclinical consultancy, Phase I and Early Phase trials, Phase II+ and Late Phase multi-regional studies, and the proprietary GlobalReady end-to-end drug development process. The company also operates specialized Centers of Excellence in CNS, Oncology, Renal & Cardiometabolic, and Early Phase, serving biotech sponsors across Australia, North America, Asia, New Zealand, and Europe.

Is Avance Clinical a public or private company?

Avance Clinical is a private company. It is classified as private equity controlled and is currently operating.

When was Avance Clinical founded?

Avance Clinical was founded in 1990. It employs 251 to 500 people.

Where is Avance Clinical based?

Avance Clinical is headquartered in Adelaide, Australia, in the Oceania region.

How does Avance Clinical make money?

One revenue line is on record: contract Research Organization Services.

Who are Avance Clinical's main competitors?

Broad incumbents on record are PPD (Thermo Fisher Scientific), Parexel, Medpace, ICON plc, Labcorp Drug Development, IQVIA and Charles River Laboratories. Direct peers are Worldwide Clinical Trials, Simbec-Orion and Novotech.

Does Avance Clinical have an API?

No public API is recorded for Avance Clinical.

What industry is Avance Clinical in?

Avance Clinical's product category is Contract Research Organization (CRO) Services. Its primary akta.pro industry code is HLAGAAAA, Clinical CROs (Phase I–IV), with a secondary code of HLAGAAAL, Specialty Therapeutic-Area CROs (e.g., oncology/rare disease). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business & FinancialAvance Clinical Brings 30 Years Of Early-Phase And Therapeutic Leadership To European Biotechs At BIO-Europe 2026Avance Clinical will exhibit at BIO-Europe 2026 in Cologne, Germany, from 9–11 November 2026 at booth #8-24. The Australian CRO highlights its 30+ years of experience, 250+ indications, and 300+ first-in-human studies, plus a 43.5% R&D tax offset. It promotes its GlobalReady model for multi-regional expansion.GlobeNewswireAvance Clinical Brings 30 Years of Early-Phase and Therapeutic Leadership to European Biotechs at BIO-Europe 2026Avance Clinical will exhibit at BIO-Europe 2026 in Cologne, Germany, from 9–11 November 2026 at booth #8-24. The company highlights its 30+ years of experience, 250+ indications, and 300+ first-in-human studies, plus an Australian CTN scheme that starts trials in 5–6 weeks without an IND or EU CTA. It also offers a refundable tax offset of up to 43.5% on eligible R&D spend.The future of tradingAvance Clinical to Meet European Biotechs at ESMO Congress 2026 and Appoints Wendy Hamon as Senior Vice President, Oncology Center of ExcellenceAvance Clinical will meet European biotech sponsors at ESMO Congress 2026 in Madrid, with Dr George Peoples leading the oncology team. The company also appointed Wendy Hamon as Senior Vice President, Oncology Center of Excellence, which has delivered over 260 oncology trials in five years.FinancialContent Business PageAvance Clinical to Meet European Biotechs at ESMO Congress 2026 and Appoints Wendy Hamon as Senior Vice President, Oncology Center of ExcellenceAvance Clinical will meet European biotech sponsors at ESMO Congress 2026 in Madrid, led by Dr George Peoples. The company also appointed Wendy Hamon as Senior Vice President, Oncology Center of Excellence. The Center has delivered over 260 oncology trials in five years.FinancialContent Business PageAvance Clinical to Showcase its Early Phase Center of Excellence Model at AusBiotech International 2026Avance Clinical will exhibit at Stand #72 at AusBiotech International 2026 in Queensland, showcasing its Early Phase Center of Excellence model. The integrated operating model spans Australia, New Zealand, the US, South Korea, Taiwan, and India, aiming to reduce execution risk for sponsors. The company has partnered with over 750 biotechs across 250+ indications.GlobeNewswireAvance Clinical to Showcase its Early Phase Center of Excellence Model at AusBiotech International 2026Avance Clinical will exhibit at Stand #72 at AusBiotech International 2026 in Queensland, showcasing its Early Phase Center of Excellence model. The integrated operating model spans Australia, New Zealand, the US, South Korea, Taiwan, and India, aiming to reduce execution risk for sponsors. The company has partnered with over 750 biotech companies across 250+ indications.FinancialContent Business PageAvance Clinical Appoints Inaugural Chief Commercial Officer, Reinforcing Global Growth StrategyAvance Clinical appointed Tim Schuckman as its inaugural Chief Commercial Officer to lead commercial strategy and business development. This new executive role supports the company's expansion in North America, Asia, and Europe amid accelerating demand from biotech sponsors.AvancecroAvance Clinical announces North American CRO acquisition to expand later phase services for BiotechsAvance Clinical acquired C3 Research Associates to expand into North America, enabling biotech clients to transition from early-phase studies in Australia/New Zealand to later-phase trials in the US. The acquisition includes a 43.5% rebate on clinical spend and plans to grow the US team to over 120 people.GurufocusRevelation Biosciences Selects Avance Clinical as CRO for PhaseRevelation Biosciences has selected Avance Clinical as the contract research organization for its Phase 2/3 TITAN study evaluating Gemini for acute kidney injury. The partnership, finalized after an extensive evaluation process, aims to manage critical trial operations such as site identification and patient recruitment. Revelation plans to initiate this study later in the year.